...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Cancer research: The official organ of the American Association for Cancer Research, Inc >A synthetic lethality-based strategy to treat cancers harboring a genetic deficiency in the chromatin remodeling factor BRG1-Letter
【24h】

A synthetic lethality-based strategy to treat cancers harboring a genetic deficiency in the chromatin remodeling factor BRG1-Letter

机译：一种基于合成杀伤力的策略，用于治疗染色质重塑因子BRG1-Letter中存在遗传缺陷的癌症

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

We would like to comment on a recently published research article in your journal, entitled "A Synthetic Lethality-Based Strategy to Treat Cancers Harboring a Genetic Deficiency in the Chromatin Remodeling Factor BRG1," by Oike and colleagues (I). This article attempts to demonstrate that BRGl-deficient cancer cells can be inhibited by the suppression of the homolog SWI/SNF catalytic subunit, Brahma (BRM). This is an intriguing concept, which if correct would present potential new therapeutic avenues. The thrust of this article, however, appears seemingly contradictory to a subset of published data from a number of different laboratories about the functional roles of BRG1 and BRM in cancer. In this letter, we would like to promote a balanced discussion by covering those data that both oppose and support this publication as well as explain how these diverging observations might be reconciled.
机译：我们想评论一下您的期刊上最近发表的一篇研究文章，作者为Oike和同事（I），题为“一种基于合成致死性的策略来治疗在染色质重塑因子BRG1中存在遗传缺陷的癌症”。本文试图证明缺乏BRG1的癌细胞可以通过抑制同源SWI / SNF催化亚单位Brahma（BRM）来抑制。这是一个有趣的概念，如果正确，它将提出潜在的新治疗途径。然而，本文的主旨似乎与来自许多不同实验室的关于BRG1和BRM在癌症中的功能作用的已发表数据的一部分相矛盾。在这封信中，我们希望通过涵盖既反对又支持本出版物的数据，并解释如何调和这些分歧意见，以促进平衡的讨论。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号